Sophiris Bio Q3 net loss widens
Expenses for third quarter of 2012 were $5.39m compared to $2.64m for the third quarter of 2011. The company reported a net loss of $15.84m, or $0.10 per
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
The voice recognition technology was designed to confirm prescription medications before administration at home or in medical center, thereby preventing medication errors. SafeCode technology provides access to prescription
The models, which were developed using the GNS’s supercomputer-driven Reverse Engineering and Forward Simulation (REFS) platform, will assist researchers in discovering novel therapies for the disease and determine
The Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) that randomised 861 metastatic pancreatic cancer patients with either Abraxane along with gemcitabine or gemcitabine alone met its primary endpoint of
The registration allows the recovery, processing, packaging, storage, and labeling of human cells and tissue products (HCT/P’s) including the company’s autologous stromal vascular fraction cellular product at the
The collaboration will leverage Chiromics’ compound collections of accessible complexity, Chalis, hit recognition algorithm designed for affinity screening. Chiromics founder David MacMillan and Princeton University chemistry department chairman